Why the study?
Does aspirin therapy reduce all-cause mortality and late coronary revascularization in patients with non-obstructive CAD?
Does aspirin therapy reduce all-cause mortality and late coronary revascularization in patients with non-obstructive CAD?
In patients with non-obstructive CAD, aspirin therapy is associated with lower all-cause mortality primarily in those with higher clinical risk profiles.
Authors
No takes yet. Share an insight, caveat, or question.
Does not support changing aspirin practice in non-obstructive CAD; leaves open confirmation of mortality benefit in RCTs.
Hwang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: